Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Feb 15;10(4):525-30.
doi: 10.3748/wjg.v10.i4.525.

Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma

Affiliations

Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma

Gassimou Bangoura et al. World J Gastroenterol. .

Abstract

Aim: To investigate the expression of hypoxia-inducible factor (HIF)-2alpha/endothelial PAS domain protein1 (EPAS1) in hepatocellular carcinoma (HCC).

Methods: Expression of HIF-2alpha/EPAS1 was investigated immunohistochemically on paraffin-embedded sections from 97 patients with HCC. To further confirm that HIF-2alpha/EPAS1 in HCC tissues also correlated with angiogenesis, a parallel immunohistchemistry study of vascular endothelial growth factor (VEGF) was performed on these 97 cases.

Results: HIF-2alpha/EPAS1 could be detected in 50 of 97 cases (51.6%), including 19 weakly positive (19.8%), and 31 strongly positive (31.1%), the other 47 cases were negative (48.4%). The expression of HIF-2alpha/EPAS1was significantly correlated with tumor size, capsule infiltration, portal vein invasion, and necrosis. A parallel immunohistochemical analysis of VEGF demonstrated its positive correlation with capsule infiltration, portal vein invasion, and HIF-2alpha/EPAS1 overexpression, which supported the correlation of HIF-2alpha/EPAS1up-regulation with tumor angiogenesis. No apparent correlation was observed between HIF-2alpha/EPAS1 and capsular formation, presence of cirrhosis, and histological grade.

Conclusion: HIF-2alpha/EPAS1 is expressed in most of HCC with capsular infiltration and portal vein invasion, which indicates a possible role of HIF-2alpha/EPAS1 in HCC metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Characterization of HIF-2α/EPAS1 expression in human hepatocellular carcinoma tissues by IHC technique. A: Weak expression of HIF-2α/EPAS1 in membranes and cytoplasms of HCC cells (× 400). B: Strong cytoplasmic immunoreactivity of HIF-2α/EPAS1 in HCC cells (× 400). C: HIF-2α/EPAS1 positive staining (arrows) in perinecrotic region near tumor in a HCC sample (with capsular infiltration and portal vein invasion) (× 400). D: Strong HIF-2α/EPAS1 expression in HCC tissues whereas no staining in adjacent stroma cells (× 400). E: Strong staining in the cytoplasm of macrophages compared with cancer cells, showing weak staining for HIF-2α/EPAS1 (× 400). F: Moderate to strong positive staining of HIF-2α/EPAS1 in tumor clusters infiltrating to the tissue (× 400).
Figure 2
Figure 2
Parallel study of VEGF protein expression in HCC samples. A mAb against VEGF was used for immunostainig of slides from HCC patients. A: HCC with capsular infiltration and portal vein invasion showing strong staining (++) in the cytoplasm of tumor cells. B: HCC without capsular infiltration and portal vein invasion showing weak staining (+) (× 200).

References

    1. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 1998;12:149–162. - PMC - PubMed
    1. Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc Natl Acad Sci USA. 2000;97:8386–8391. - PMC - PubMed
    1. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997;11:72–82. - PubMed
    1. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000;14:1983–1991. - PubMed
    1. Morrow CS, Cowan KH. Antineoplastic drug resistance and breast cancer. Ann N Y Acad Sci. 1993;698:289–312. - PubMed

Publication types

Substances